Option chain shows key data for Intuitive Surgical's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Intuitive Surgical.

Intuitive Surgical (NASDAQ:ISRG) Stock, Option Chain

Intuitive Surgical

Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 installations in the US and a growing number in emerging markets.

Bernie's Concerns With Healthcare Costs

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

BBIO

ISRG

ITCI

Top 4 Health Care Stocks You May Want To Dump In Q1

Modern,Hospital,Style,Building

Short Sellers

Health Care

General

PRCT

Spruce Point Capital warns of Procept BioRobotics&#39; overstated market potential and growth claims, citing niche product limitations and valuation risks.

Spruce Point Sees Trouble Ahead For Procept BioRobotics

The Struggles of Traditional Car Stocks

Equities

QUBT

TSLA

The U.S. stock market experienced a robust session with the Nasdaq Composite climbing 2.45% to 19,511.23.

Quantum Computing, Taiwan Semiconductor, Meta, Intuitive Surgical, And Tesla: Why These 5 Stocks Are On Investors&#39; Radars Today

Intuitive Surgical Inc

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 20 years by 19.56% on an annualized basis producing an average annual return of 28.09%. Currently, Intuitive Surgical has a market capitalization of $215.49 billion. 
Buying $100 In ISRG: If an investor had bought $100 of ISRG stock 20 years ago, it would be worth $13,941.23 today based on a price of $605.00 for ISRG at the time of writing.
<h3>Intuitive Surgical's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737499516_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Intuitive Surgical 20 Years Ago Would Be Worth Today

Intuitive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today it intends to establish a direct presence in Italy, Spain, Portugal, Malta, and San Marino, and associated territories via the acquisition of the da Vinci and Ion distribution businesses in these countries.
Intuitive has entered into this agreement, subject to regulatory approvals, with the current Intuitive technology distributors ab medica, Abex, Excelencia Robotica, and their affiliates to purchase their Intuitive product-related business. The transaction will not close until 2026, after approvals have been received and closing conditions met.

Global

Intuitive Announced Acquisition Of Da Vinci And Ion Distribution Businesses In Italy, Spain, Portugal, Malta, And San Marino; Deal Expected To Close By 2026; No Financial Terms Disclosed

As of Jan. 21, 2025, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to<a href="https://pro.benzinga.com/"> Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">BridgeBio Pharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>)</h3>
<ul>
<li>On Nov. 22, the FDA approved BridgeBio Pharma's Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization.. The company's stock surged around 28% over the past month and has a <a href="https://www.benzinga.com/quote/BBIO">52-week high of $41.04</a>.</li>
<li>RSI Value: 71.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>BBIO Price Action: Shares of BridgeBio Pharma fell 0.9% to close at $33.79 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>)</h3>
<ul>
<li>On Jan. 15, Intuitive Surgical reported strong preliminary fourth-quarter results. "We are pleased with customer adoption of da Vinci 5, Ion, and SP during the quarter and full year. We remain focused on delivering the goals we share with our customers, centered on improving patient outcomes," said Gary Guthart, CEO of Intuitive Surgical. The company's stock gained around 9% over the past five days and <a href="https://www.benzinga.com/quote/ISRG">has a 52-week high</a> of $597.68.</li>
<li>RSI Value: 72.6</li>
<li>ISRG Price Action: Shares of Intuitive Surgical gained 1.5% to close at $592.64 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Boston Scientific Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>)</h3>
<ul>
<li>On Jan. 8, Boston Scientific agreed to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy (IVL) advanced laser-based platform for coronary and peripheral artery disease. The company's stock gained around 11% over the past month and has a <a href="https://www.benzinga.com/quote/BSX">52-week high</a> of $99.14.</li>
<li>RSI Value: 75.3</li>
<li>BSX Price Action: Shares of Boston Scientific gained 0.5% to close at $98.66 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Intra-Cellular Therapies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>)</h3>
<ul>
<li>On Jan. 13, Johnson &amp; Johnson entered into a definitive agreement to acquire all outstanding shares of Intra-Cellular Therapies for $132 per share in cash in a deal that values the company at approximately $14.6 billion. The company's stock jumped around 51% over the past month and has a 52-week high is $128.00.</li>
<li>RSI Value: 85.6</li>
<li>ITCI Price Action: Shares of Intra-Cellular Therapies fell 0.05% to close at $126.20 on Friday. </li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43054647/wall-streets-most-accurate-analysts-spotlight-on-3-financial-stocks-with-over-9-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Financial Stocks With Over 9% Dividend Yields</a></li>
</ul>

Investors with a lot of money to spend have taken a bearish stance on Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ISRG, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Intuitive Surgical.
This isn't normal.
The overall sentiment of these big-money traders is split between 12% bullish and 75%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $226,650, and 5 are calls, for a total amount of $178,590.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $525.0 and $585.0 for Intuitive Surgical, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Intuitive Surgical's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Intuitive Surgical's substantial trades, within a strike price spectrum from $525.0 to $585.0 over the preceding 30 days.
<h3>Intuitive Surgical Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737127838_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$20.7</td>
<td>$19.5</td>
<td>$20.5</td>
<td>$540.00</td>
<td>$123.0K</td>
<td align="right">103</td>
<td align="right">61</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$66.8</td>
<td>$62.5</td>
<td>$65.4</td>
<td>$540.00</td>
<td>$65.4K</td>
<td align="right">75</td>
<td align="right">54</td>
</tr>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$35.0</td>
<td>$33.8</td>
<td>$34.6</td>
<td>$580.00</td>
<td>$51.9K</td>
<td align="right">7</td>
<td align="right">31</td>
</tr>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$34.9</td>
<td>$33.6</td>
<td>$34.5</td>
<td>$580.00</td>
<td>$51.7K</td>
<td align="right">7</td>
<td align="right">15</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$17.9</td>
<td>$14.7</td>
<td>$14.7</td>
<td>$570.00</td>
<td>$29.4K</td>
<td align="right">424</td>
<td align="right">21</td>
</tr>
</tbody>
</table>

<h3>About Intuitive Surgical</h3>
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 installations in the US and a growing number in emerging markets.
In light of the recent options history for Intuitive Surgical, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Intuitive Surgical</h3>
<ul>
<li>Trading volume stands at 612,694, with ISRG's price up by 0.28%, positioned at $585.74.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 6 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Intuitive Surgical options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

A Closer Look at Intuitive Surgical's Options Market Dynamics

On Thursday, <a href="https://www.benzinga.com/topic/spruce-point-capital">Spruce Point Capital released</a> a detailed report on PROCEPT BioRobotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>), raising concerns about the claims surrounding its market potential and growth prospects, suggesting the company&#8217;s stock could face a 30% to 60% downside.
Spruce Point questions the credibility of Procept&#8217;s addressable market estimates, business metrics, and valuation.
Procept BioRobotics specializes in a robotic surgical system for benign prostatic hyperplasia (BPH or enlarged prostate).
Benzinga has contacted Procept for comment on the Spruce Point report and will update if a response is received.
The company&#8217;s Aquablation therapy, a waterjet procedure designed to minimize sexual side effects compared to other surgeries, has gained traction in high-volume U.S. hospitals, contributing to significant revenue growth—from under $10 million in 2020 to $200 million, according to Spruce Point.
However, Spruce Point argues that Procept's comparison to Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) is misleading and that the addressable market for Aquablation is significantly overstated.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41583831/surgical-robotics-provider-procept-biorobotics-q3-earnings-beats-street-view-analys" target="_blank" rel="noreferrer noopener">Surgical Robotics Provider PROCEPT BioRobotics&#8217; Q3 Earnings Beats Street View, Analyst Optimistic About Upside Potential</a>
Spruce Point <a target="_blank" href="https://www.businesswire.com/news/home/20250116281668/en/Spruce-Point-Capital-Management-Announces-Investment-Opinion-Releases-Report-and-Strong-Sell-Research-Opinion-on-PROCEPT-BioRobotics-NASDAQ-PRCT" rel="noreferrer noopener">writes</a> that Aquablation&#8217;s appeal is limited to a niche segment of patients with large prostates, representing only a small fraction of the BPH market. Most BPH patients suffer from mild to moderate symptoms, often managed with medications or minimally invasive surgical therapies (MISTs).
These outpatient procedures, offering minimal risks and shorter recovery times, have rapidly gained market share since 2014, accounting for 40-45% of BPH surgeries. Spruce Point says MISTs will continue to outpace resective procedures like Aquablation.
Further concerns stem from Procept's rising days sales outstanding (DSOs), which have increased from 47 to 130 days over three years, signaling potential sales and accounting issues.
Spruce Point also found inconsistencies in Procept's reported surgical volumes and equipment utilization rates, raising doubts about the company's metrics.
Procept&#8217;s statements regarding its robotic and AI capabilities have faced scrutiny. Critics, including Spruce Point Capital Management, argue that the system&#8217;s reliance on sales representatives during procedures and the need for surgeon expertise undermines its &#8220;automation&#8221; narrative. The HYDROS system, introduced with promises of AI-driven advancements, has been met with mixed feedback, with some urologists finding its features underwhelming.
Despite Procept&#8217;s $4.7 billion market valuation and premium revenue multiple, Spruce Point argues that its niche product, structural barriers to growth, and questionable metrics make its valuation unsustainable. The firm estimates Procept's fair value at $29 to $54 per share, implying substantial downside risk.
Price Action: PRCT stock is down 1.79% at $76.91 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43034421/whats-going-on-with-rtx-corporation-stock-today" target="_blank" rel="noreferrer noopener">RTX Lands $529M Contract To Bolster Dutch Missile Defense: Details</a></li>
</ul>
Photo: Shutterstock

The U.S. stock market experienced a robust session with the Nasdaq Composite climbing 2.45% to 19,511.23 and the S&amp;P 500 rising by 1.8% to 5,949.91. The Dow Jones Industrial Average also saw gains, increasing by 1.65% to 43,221.55. 
These are the top stocks that gained the attention of retail traders and investors throughout the day:
Quantum Computing Inc.
Quantum Computing Inc. shares soared by 55.45%, closing at $11.55. The stock reached an intraday high of $11.60 and a low of $8.51, with a 52-week range of $27.15 to $0.35. The surge followed <a href="https://www.benzinga.com/25/01/43004816/whats-going-on-with-quantum-computing-stock-today">NVIDIA Corp.&#8217;s announcement</a> of its inaugural Quantum Day, scheduled for March 20 during the GTC 2025 event. This announcement comes shortly after CEO Jensen Huang mentioned that practical quantum computing might still be two decades away. Additionally, Microsoft Corporation&#8217;s plans to make its business clients &#8220;quantum-ready&#8221; by 2025 added to the excitement.
Taiwan Semiconductor Manufacturing Co.
Taiwan Semiconductor&#8217;s stock rose by 2.61%, closing at $206.80. The day&#8217;s trading saw a high of $209.04 and a low of $199.35, with a 52-week range of $222.20 to $100. The company is set to release its fourth-quarter financial results, with analysts expecting a fifth consecutive revenue beat. The anticipated revenue is $26.28 billion, up from $19.62 billion in the same quarter last year, driven by strong semiconductor demand and <a href="https://www.benzinga.com/25/01/43015316/taiwan-semiconductor-q4-earnings-preview-analysts-expect-fifth-straight-beat-will-investors-get-comments-on-trump-impact">potential benefits</a> from the new U.S. administration.
Meta Platforms Inc.
Meta Platforms saw a 3.85% increase, closing at $617.12. The stock hit an intraday high of $622.46 and a low of $606.50, with a 52-week range of $638.40 to $358.61. An internal memo revealed <a href="https://www.benzinga.com/media/25/01/42995912/meta-plans-to-cut-5-of-staff-backfill-roles-in-2025-says-internal-memo">plans for performance-based job cuts</a>, aiming for a 10% &#8220;non-regrettable attrition&#8221; rate by the end of the current performance cycle. This strategy involves classifying employees into performance tiers based on their contributions over the past year.
Intuitive Surgical Inc.
Intuitive Surgical&#8217;s shares jumped by 7.65%, closing at $580.11. The stock reached an intraday high of $584.60 and a low of $549.17, with a 52-week range of $584.60 to $355.17. The increase followed the company&#8217;s&nbsp;<a href="https://www.benzinga.com/news/earnings/25/01/43007218/why-intuitive-surgical-shares-are-surging-wednesday">preliminary fourth-quarter results</a>, which showed expected revenue of approximately $2.41 billion, surpassing analyst estimates of $2.2 billion. The company also reported a significant growth in da Vinci procedures and system placements.
Tesla, Inc.
Tesla&#8217;s stock rose by 8.04%, closing at $428.22. The day&#8217;s trading saw a high of $429.80 and a low of $405.66, with a 52-week range of $488.54 to $138.80. The rise was influenced by recent data from Kelley Blue Book ranking Tesla&#8217;s Model Y and Model 3 as the top-selling electric vehicles. Despite selling about 37,000 fewer cars in 2024 compared to 2023, Tesla <a href="https://www.benzinga.com/25/01/43014719/whats-going-on-with-tesla-shares-wednesday">maintained its lead</a> in the EV market, with increased competition noted as a factor.
Image via Shutterstock
Prepare for the day&#8217;s trading <a href="https://editorial.benzinga.com/wp-admin/Premarket%20Movers%20&amp;%20News">with top premarket movers and news</a> by Benzinga.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/43018900/from-adani-to-nikola-how-hindenburg-research-reshaped-short-selling-before-its-final-bow">From Adani To Nikola: How Hindenburg Research Reshaped Short-Selling Before Its Final Bow</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Quantum Computing, Taiwan Semiconductor, Meta, Intuitive Surgical, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

Wall Street staged a strong rebound on Wednesday, as mixed inflation data bolstered investor confidence in the Federal Reserve's continuation of easing cycle in 2025, <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43001512/inflation-rises-to-29-in-december-core-slows-yet-rising-energy-costs-put-feds-target-at-risk">easing recent market anxieties.</a>
The headline Consumer Price Index rose 2.9% year-over-year in December, up from November&#8217;s 2.7% and aligning with economist forecasts. On a monthly basis, headline inflation increased by 0.4%, up from November&#8217;s 0.3%, marking the sharpest monthly rise since March 2024.
The inflation report strengthened market expectations for Fed rate cuts in 2025. The probability of a rate cut by June climbed to 63%, up from 55% the previous day, with December futures now pricing in a 50% chance of two rate cuts.
The S&amp;P 500 advanced 1.5% by midday trading in New York, and the Dow Jones followed suit with a similar gain, both supported by strength in financial stocks. The Nasdaq 100 outperformed, rising 1.9%, while small-cap stocks posted a 1.7% gain.
Key financial giants, including JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>), Bank of New York Mellon Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>), and BlackRock Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>), exceeded Wall Street's <a href="https://www.benzinga.com/news/earnings/25/01/43007354/big-banks-crush-q4-earnings-forecasts-financial-stocks-set-for-biggest-1-day-rally-since-trumps-election">fourth-quarter 2024 earnings expectations.</a>
The Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) surged nearly 2.2%, leading all S&amp;P 500 sectors and recording its strongest one-day gain in over two months.
In the bond market, yields on the 2-year Treasury note, which is highly sensitive to interest rate expectations, fell 9 basis points to 4.28%, while 30-year yields dropped 8 basis points to 4.89%. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) gained 1.3% as bond prices rose.
The U.S. Dollar Index (DXY), as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), remained flat, with dollar strength against the euro offset by weakness versus the yen.
West Texas Intermediate — as tracked by the United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>) — rallied 2%, hitting $80 a barrel during the day amid a stronger-than-expected drop in commercial crude stocks last week.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) jumped 2.6%, nearing $99,000, buoyed by optimism surrounding potential Fed rate cuts. Meanwhile, gold, tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), gained 0.5%. 
<h1 class="wp-block-heading">Wednesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,142.06</td>
<td>1.9%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,257.59</td>
<td>1.7%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,932.76</td>
<td>1.5%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>43,153.53</td>
<td>1.5%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:15 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1.5% to $590.96.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 1.5% to $431.31.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rallied 1.9% to $514.49.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) increased 1.8% to $223.77.</li>
<li>The&nbsp;Financial Select Sector SPDR Fund outperformed, up 1.2%; the&nbsp;Consumer Staples Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) lagged, down 0.3%.</li>
</ul>
<h3 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h3>
<ul>
<li>Citigroup Inc. rallied over 7%, in reaction to stronger-than-expected earnings, marking the strongest performance within the S&amp;P 500 index.</li>
<li>Intuitive Surgical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) rose 6.9% after RBC raised its 12-month price target to $641. </li>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares climbed more than 5% after RBC increased its price target for the stock from $313 to $440, while reaffirming its outperform rating.</li>
</ul>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43006771/bitcoin-up-to-99000-is-loving-inflation-data-release-xrp-dogecoin-follow-higher">Bitcoin Up To $99,000 &#8216;Is Loving&#8217; Inflation Data Release, XRP, Dogecoin Follow Higher</a></li>
</ul>
Photo: Shutterstock

Large Cap

Macro Economic Events

Bonds

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

iShares Trust Barclays 20+ Year Treasury Bond Fund

PowerShares DB US Dollar Index Bullish Fund

Wall Street Rallies As Treasury Yields Fall, Banks Smash Q4 Earnings, Oil Hits $80: What's Driving Markets Wednesday?

Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) shares are trading higher Wednesday after the company reported preliminary financial results <a href="https://www.benzinga.com/pressreleases/25/01/g43002040/intuitive-announces-preliminary-fourth-quarter-and-full-year-2024-results">for the fourth quarter</a>. 
What Happened: Intuitive Surgical said it expects to report fourth-quarter revenue of approximately $2.41 billion, versus analyst estimates of $2.2 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. 
The company expects worldwide da Vinci procedures&nbsp;to grow approximately&nbsp;18%&nbsp;compared with the&nbsp;fourth quarter&nbsp;of 2023. Intuitive Surgical expects to report 493 da Vinci surgical systems placed in the quarter. 
&#8220;We are pleased with customer adoption of da Vinci 5, Ion, and SP during the quarter and full year. We remain focused on delivering the goals we share with our customers, centered on improving patient outcomes,&#8221; said Gary Guthart, CEO of Intuitive Surgical. 
Intuitive Surgical released its preliminary results ahead of a presentation Wednesday at the 2025 J.P. Morgan Healthcare Conference. The company is scheduled to report its full fourth-quarter earnings results on Jan. 23. Intuitive Surgical noted that it will discuss the quarter in more detail at that time. 
See Also:<a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43001512/inflation-rises-to-29-in-december-core-slows-yet-rising-energy-costs-put-feds-target-at-risk"> Inflation Rises To 2.9% In December: Core Slows, Yet Rising Energy Costs Put Fed&#8217;s Target At Risk</a>
<h3 class="wp-block-heading">How To Buy ISRG Stock</h3>
By now you're likely curious about how to participate in the market for Intuitive Surgical &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share. In the case of Intuitive Surgical, which is trading at $538.88 as of publishing time, $100 would buy you 0.19 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
ISRG Price Action: <a href="https://www.benzinga.com/quote/ISRG" target="_blank" rel="noreferrer noopener">Intuitive Surgical shares</a> were up 6.40% at $573.40 at the time of publication Wednesday, according to <a href="https://benzinga.grsm.io/gxjhpowx7zks" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: courtesy of Intuitive Surgical.

Earnings

Guidance

Movers

Why Intuitive Surgical Shares Are Surging Wednesday

Major indices rallied on Wednesday after December inflation data showed underlying price pressures slowing, reducing fears of a prolonged pause in interest rate cuts <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43001512/inflation-rises-to-29-in-december-core-slows-yet-rising-energy-costs-put-feds-target-at-risk">by the Federal Reserve. </a>
The headline Consumer Price Index rose 2.9% year-over-year in December, up from November's 2.7%, matching economist forecasts. On a monthly basis, headline inflation increased 0.4%, accelerating from the 0.3% surge in November and marking the largest monthly rise since March 2024.
Core inflation, which excludes volatile food and energy prices, rose 3.2% year-over-year, slightly below the expected 3.3%. Month-over-month, core prices gained 0.2%, in line with forecasts.
The inflation data boosted expectations for Fed rate cuts in 2025. The probability of a rate cut by June rose to 68% from 55% the previous day, with December futures now indicating a 58% chance of two cuts by year-end.
<h3 class="wp-block-heading">Wall Street Gains As Bond Yields Retreat, Financial Stocks Soar</h3>
The S&amp;P 500 index – as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – surged 1.5% in early New York trading, led by financial stocks after major banks reported strong fourth-quarter earnings.
JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>), Bank of New York Mellon Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) and BlackRock Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) all topped earnings forecasts for the fourth quarter and released upbeat guidance, reiterating that the financial sector thrived heading to the end of last year.
The Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) rose 2.2%, leading all S&amp;P 500 sectors, while the SPDR S&amp;P Regional Banking ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRE#NYSE">KRE</a>) jumped 3.4%, reflecting strong performance among regional banks.
The Dow rose 1.6%, while the Russell 2000 index outperformed, climbing 2.6%. Tech stocks, tracked by the Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), gained 1.7%, boosted by falling Treasury yields.
Yields on the policy-sensitive 2-year Treasury note fell 9 basis points to 4.27%, while 30-year yields dropped 9 basis points to 4.88%. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) gained 1.6% as bond prices rallied.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose 2% to over $99,000, supported by rising hopes for Fed rate cuts. Gold, tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), added 0.5%.
<h3 class="wp-block-heading">Top Movers</h3>
S&amp;P 500 Gainers:
<ul>
<li>Texas Pacific Land Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPL#NYSE">TPL</a>): +5.85%</li>
<li>BlackRock Inc.: +5.54%</li>
<li>Assurant Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>): +5.49%</li>
<li>Bio-Techne Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>): +5.36%</li>
<li>Citigroup Inc.: +5.16%</li>
</ul>
Nasdaq 100 Movers:
<ul>
<li>Copart Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>): +4.62%</li>
<li>Intuitive Surgical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>): +4.60%</li>
<li>AppLovin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>): +4.43%</li>
<li>Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>): +4.30%</li>
<li>The Trade Desk Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>): +3.39%</li>
</ul>
Top Gainers In The Invesco KBW Bank ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBWB#NYSE">KBWB</a>):
<ul>
<li>Citigroup Inc.: +5.27%</li>
<li>Wells Fargo &amp; Co.: +4.80%</li>
<li>Bank of New York Mellon Corp.: +4.35%</li>
<li>Western Alliance Bancorp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>): +4.13%</li>
<li>Goldman Sachs Group Inc.: +4.02%</li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43000684/jpmorgan-q4-earnings-shine-investment-banking-revenue-jumps-46-yy-jamie-dimon-says-inflation-may-persist-for-some-time">JPMorgan Chase Q4 Earnings: Investment Banking Revenue Jumps 46%, CEO Jamie Dimon Says &#8216;Inflation May Persist For Some Time&#8217;</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Small Cap

Federal Reserve

Tech

CPRT

KBWB

PLTR

TECH

Stocks Rise On Core Inflation Slowdown, Banks Rally After Strong Q4 Earnings, Treasury Yields Plummet

WIIM

Intuitive Surgical shares are trading higher after the company reported strong preliminary Q4 results.

Intuitive Prelim. Q4 Results; Q4 Worldwide Da Vinci Procedures Grew Approximately 18% YoY, Da Vinci System Placements Totaled 493

Intuitive Sees Prelim. Q4 Revenue ~$2.41B vs $2.204B Est.; FY24 Revenue $8.35B

Scorpion Capital, on Friday, disclosed a short seller report on TransMedics Group Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), accusing the organ transplant technology company of fraudulent practices, including kickbacks, billing fraud and <a href="https://www.benzinga.com/quote/TMDX" target="_blank" rel="noreferrer noopener">unreported device failures</a>.
Scorpion alleges that TransMedics engages in &#8220;mafia-style&#8221; practices, including coercion, billing fraud, and the manipulation of organ allocation, operating under the guise of a legitimate medical device company.
The report sets a price target of $0.
The company said the allegations are inaccurate and misleading. &#8220;We strongly believe that the claims made in the Scorpion Capital report have no merits and were primarily intended to manipulate the <a href="https://www.benzinga.com/pressreleases/25/01/n42940808/transmedics-responds-to-inaccurate-and-misleading-claims-in-recent-short-seller-report" target="_blank" rel="noreferrer noopener">market for financial gains</a>,&#8221; TransMedics said in a statement.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/management/24/12/42290942/transmedics-ushers-in-new-cfo-tightens-2024-revenue-goals" rel="noreferrer noopener">TransMedics Ushers In New CFO, Tightens 2024 Revenue Goals</a>
The report said TransMedics operates like an airline with a medical device component, trading at an expensive valuation of seven times its last 12 months&#8217; revenue.
By a more relevant metric, enterprise value to product sales, the ratio is 10 times – which Scorpion Capital describes as extraordinarily high, especially <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41608129/organ-transplant-medtech-transmedics-q3-performance-disappoints-analyst-outlines-in" target="_blank" rel="noreferrer noopener">as sales are declining</a>.
This makes TransMedics the most expensive mid-cap medtech company in the U.S. and the third-highest overall, behind Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) and Glaukos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), according to Scorpion Capital. 
Even at a more reasonable multiple of 5 times product sales, TransMedics&#8217; stock would drop to the $30 range.
The company has no free cash flow and only recently turned slightly profitable, a trend likely to reverse with declining sales.
Scorpion stated in its report, &#8220;TransMedics is the most extreme and grotesque healthcare fraud we have encountered, not only for its scale, but because it is predicated on the exploitation of the most vulnerable patients &#8212; the terminally ill, desperate for an organ.&#8221;
The short seller <a target="_blank" href="https://scorpionreports.s3.us-east-2.amazonaws.com/TMDX.pdf" rel="noreferrer noopener">alleged</a> that TransMedics &#8220;pushes unsafe, damaged organs rejected by reputable centers, as an unplaced organ means loss of device and aircraft fees, with TransMedics allegedly concealing adverse organ information.&#8221;
Scorpion Capital announced plans to file a Citizen Petition with the FDA, requesting the suspension of Premarket Approval (PMA) for TransMedics&#8217; Organ Care System (OCS). The short seller also said it intends to send a public letter to members of Congress probing abuses in the U.S. organ transplant system.
In April, the FDA granted PMA to the OCS Heart System for use with organs from donors after circulatory death, following a PMA approval of the System after brain death received <a href="https://www.benzinga.com/pressreleases/22/04/n26862717/transmedics-receives-fda-pma-approval-of-ocs-dcd-heart-indication" target="_blank" rel="noreferrer noopener">in September 2021</a>.
Price Action: TMDX stock is down 12.6% at $60.10 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42949261/eli-lilly-scoops-up-scorpion-therapeutics-early-stage-cancer-program-for-25-billion" target="_blank" rel="noreferrer noopener">Eli Lilly Scoops Up Scorpion Therapeutics&#8217; Early-Stage Cancer Program For $2.5 Billion</a></li>
</ul>
Photo: Tigarto/Shutterstock.com

GKOS

TMDX

Short Seller Accuses TransMedics Of 'Mafia Style' Scheme, Organ Transplant Company Says Short Seller Manipulating Market

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 10 years by 13.26% on an annualized basis producing an average annual return of 24.63%. Currently, Intuitive Surgical has a market capitalization of $185.93 billion. 
Buying $100 In ISRG: If an investor had bought $100 of ISRG stock 10 years ago, it would be worth $913.28 today based on a price of $522.00 for ISRG at the time of writing.
<h3>Intuitive Surgical's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735740008_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

Deep-pocketed investors have adopted a bearish approach towards Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ISRG usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Intuitive Surgical. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 0% leaning bullish and 87% bearish. Among these notable options, 5 are puts, totaling $161,200, and 3 are calls, amounting to $223,830.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $310.0 and $560.0 for Intuitive Surgical, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Intuitive Surgical stands at 128.0, with a total volume reaching 495.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Intuitive Surgical, situated within the strike price corridor from $310.0 to $560.0, throughout the last 30 days.
<h3>Intuitive Surgical Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734623181_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$229.5</td>
<td>$225.5</td>
<td>$225.5</td>
<td>$310.00</td>
<td>$112.7K</td>
<td align="right">112</td>
<td align="right">5</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$110.5</td>
<td>$107.3</td>
<td>$107.3</td>
<td>$540.00</td>
<td>$75.1K</td>
<td align="right">217</td>
<td align="right">36</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$37.2</td>
<td>$35.1</td>
<td>$35.97</td>
<td>$560.00</td>
<td>$35.9K</td>
<td align="right">149</td>
<td align="right">11</td>
</tr>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$32.9</td>
<td>$31.9</td>
<td>$32.9</td>
<td>$530.00</td>
<td>$32.9K</td>
<td align="right">34</td>
<td align="right">161</td>
</tr>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$32.9</td>
<td>$31.9</td>
<td>$32.9</td>
<td>$530.00</td>
<td>$32.9K</td>
<td align="right">34</td>
<td align="right">114</td>
</tr>
</tbody>
</table>

<h3>About Intuitive Surgical</h3>
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 installations in the US and a growing number in emerging markets.
<h3>Present Market Standing of Intuitive Surgical</h3>
<ul>
<li>Currently trading with a volume of 282,168, the ISRG's price is up by 1.66%, now at $535.2. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 33 days.</li>
</ul>
<h3>What Analysts Are Saying About Intuitive Surgical</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $618.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Showing optimism, an analyst from Morgan Stanley upgrades its rating to Overweight with a revised price target of $650. 
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Intuitive Surgical, which currently sits at a price target of $610. 
&#x2A; An analyst from BTIG has decided to maintain their Buy rating on Intuitive Surgical, which currently sits at a price target of $561. 
&#x2A; An analyst from Truist Securities persists with their Buy rating on Intuitive Surgical, maintaining a target price of $640. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Intuitive Surgical, maintaining a target price of $630. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Intuitive Surgical options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Behind the Scenes of Intuitive Surgical's Latest Options Trends

Truist Securities analyst Richard Newitter maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Buy and raises the price target from $570 to $640.

Price Target

Analyst Ratings

Truist Securities Maintains Buy on Intuitive Surgical, Raises Price Target to $640

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 5 years by 8.96% on an annualized basis producing an average annual return of 22.57%. Currently, Intuitive Surgical has a market capitalization of $194.20 billion. 
Buying $100 In ISRG: If an investor had bought $100 of ISRG stock 5 years ago, it would be worth $277.84 today based on a price of $545.23 for ISRG at the time of writing.
<h3>Intuitive Surgical's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734364809_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Intuitive Surgical 5 Years Ago Would Be Worth This Much Today

Citigroup analyst Joanne Wuensch maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Buy and raises the price target from $567 to $640.

Citigroup Maintains Buy on Intuitive Surgical, Raises Price Target to $640

U.S. competitiveness takes center stage in 2025 with four key investment themes—energy independence, defense innovation, infrastructure, and automation—poised to bolster portfolio growth. Global X's 2025 Investment Outlook, led by Scott Helfstein, highlights these transformative trends as critical drivers of resilience <a href="https://www.benzinga.com/topic/us-economy">in the coming year.</a>
<h2 class="wp-block-heading">Infrastructure Gets A Glow-Up</h2>
America&#8217;s infrastructure renaissance is going full throttle, with $700 billion in spending set to energize construction, equipment, and materials companies. This may bode well for investors in the Industrial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>).
These stalwarts of the old economy are reinventing themselves with cutting-edge tech to expand margins—all while trading at attractive valuations compared to the broader S&amp;P 500.
<h2 class="wp-block-heading">The Defense Play: Beyond Jets &amp; Ships</h2>
Global tensions are driving a pivot from traditional defense platforms to high-tech solutions like AI-driven drones and cybersecurity systems. 
Palantir Technologies Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) Artificial Intelligence Platform and International Business Machines Corp&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) WatsonX AI come to mind here.
Defense revenues are expected to jump nearly 10%, with margins climbing from 5.2% to 7.6%. Success will favor those adopting automation and next-generation technologies in this competitive landscape.
Read Also: <a href="https://www.benzinga.com/news/small-cap/24/12/42438879/manufacturing-tariffs-small-cap-could-steal-the-show-in-2025">Manufacturing Comeback? Strategist Expects Tariffs To Help Small-Cap Stocks But Weigh On Consumers</a>
<h2 class="wp-block-heading">Automation &amp; Onshoring: A Tech Revolution</h2>
With the U.S. accelerating its onshoring efforts, automation and AI are emerging as the driving forces powering the shift.
Software companies and data centers are prepping for a revenue surge, with mega-cap tech upping its spending on data centers to $250 billion in 2025. 
Robotics and IoT hardware could also rebound from a sales plateau, making the automation sector one to watch. Companies enabling robotics and automation such as Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), ABB (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ABBNY#OTC">ABBNY</a>), Rockwell Automation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>), Zebra Technologies&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>), Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) and UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) come to mind.
<h2 class="wp-block-heading">Energy Independence Goes Nuclear</h2>
Energy's next frontier? Nuclear. With mega-cap tech giants eyeing modular nuclear reactors as a green and reliable power source, demand for uranium is heating up. Beyond the U.S., countries like Japan and Germany are also jumping on the nuclear bandwagon, signaling a global shift toward energy resilience.
U.S. companies such as Constellation Energy&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>), Cameco&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>) and NuScale Power&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) come to mind.
Helfstein's roadmap suggests a year of targeted strategies. By aligning portfolios with these U.S.-centric themes, investors might not just weather volatility—they could thrive in the chaos.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/24/12/42437267/berkshire-palantir-etfs-add-high-octane-trading-options-with-direxions-launch">Berkshire, Palantir ETFs Add High-Octane Trading Options With Direxion&#8217;s Launch</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

Sector ETFs

ABBNY

NVDA

PATH

ZBRA

2025 Investment Themes: AI, Energy, Defense Redefine US Markets

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Keybanc raised the price target for Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) from $96 to $100. Keybanc analyst Bradley Thomas maintained an Overweight rating. Walmart shares closed at $94.55 on Tuesday. <a href="https://www.benzinga.com/quote/WMT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities boosted the price target for Phreesia, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) from $31 to $34. Truist Securities analyst Jailendra Singh maintained a Buy rating. Phreesia shares closed at $24.14 on Tuesday. <a href="https://www.benzinga.com/quote/PHR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo cut RxSight, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) price target from $56 to $42. Wells Fargo analyst Larry Biegelsen downgraded the stock from Overweight to Equal-Weight. RxSight shares settled at $39.17 on Tuesday. <a href="https://www.benzinga.com/quote/RXST/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer increased Trimble Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRMB#NYSE">TRMB</a>) price target from $77 to $88. Oppenheimer analyst Kristen Owen maintained an Outperform rating. Trimble shares closed at $74.12 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley cut Zenas BioPharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBIO#NASDAQ">ZBIO</a>) price target from $40 to $35. Morgan Stanley analyst Vikram Purohit maintained an Overweight rating. Zenas BioPharma shares closed at $9.50 on Tuesday.  <a href="https://www.benzinga.com/quote/ZBIO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Susquehanna boosted Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) price target from $339 to $375. Susquehanna analyst James Friedman maintained a Positive rating on the stock. Visa shares closed at $312.38 on Tuesday. See how other analysts view this stock.</li>
<li>Piper Sandler raised the price target for Synovus Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) from $56 to $64. Piper Sandler analyst Brad Milsaps maintained an Overweight rating. Synovus Financial shares settled at $55.14 on Tuesday. <a href="https://www.benzinga.com/quote/SNV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley boosted United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) price target from $88 to $130. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. United Airlines shares closed at $96.53 on Tuesday. <a href="https://www.benzinga.com/quote/UAL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo increased the price target for Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) from $549 to $630. Wells Fargo analyst Larry Biegelsen maintained an Overweight rating. Intuitive Surgical shares closed at $538.09 on Tuesday. <a href="https://www.benzinga.com/quote/ISRG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel raised Columbia Sportswear Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLM#NASDAQ">COLM</a>) price target from $92 to $100. Stifel analyst Jim Duffy maintained a Buy rating. Columbia Sportswear shares closed at $90.09 on Tuesday. <a href="https://www.benzinga.com/quote/COLM/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42432935/top-3-health-care-stocks-that-may-collapse-this-quarter">Top 3 Health Care Stocks That May Collapse This Quarter</a></li>
</ul>

COLM

RXST

TRMB

ZBIO

Visa To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Wednesday

Earnings week ahead: JNJ, NFLX, AAL, UAL, AXP, ABT, VZ, PG, and more

IYH: Healthcare Dashboard For January

This week, several major companies will be reporting earnings. Among them are Netflix (NFLX), Johnson & Johnson (JNJ), GE Aerospace (GE), Verizon (...

Options Volatility and Implied Earnings Moves This Week, January 21 – January 24, 2025

Intuitive Surgical: Second Half 2025 Guidance Is Critical To Maintaining Current Euphoria

Beckton, Dickinson: Hold, Momentum Is Gaining, Just Need More Growth

Becton, Dickinson: Hold, Momentum Is Gaining, Just Need More Growth

Biotech stocks got little help from the JPM Conference despite some recovery to the general market.

Healthcare And Biotech Stocks Lag The Market Again

Barclays raised the firm's price target on Intuitive Surgical (ISRG) to $684 from $510 and keeps an Overweight rating on the shares. The firm says ...

Intuitive Surgical price target raised to $684 from $510 at Barclays

Intuitive announced it intends to establish a direct presence in Italy, Spain, Portugal, Malta, and San Marino, and associated territories via the ...

Intuitive Surgical to establish direct presence in Italy, Spain, Portugal

Intuitive to buy distribution businesses in Italy, Spain, Portugal

ABBV

ALLY

CNMD

COLL

CPRX

ERIC

FITB

GARP

GEHC

HRMY

IBKR

NFLX

NTRS

PCAR

RSPH

SCHW

STLD

Untitled design - 2024-12-10T185819.364

Movers & Shakers

MBOT

Palm-Sized Innovation: How Microbot Medical Is Helping Redefine Surgical Robotics

Press Releases

Neptune Medical Announces $97M Series D Financing and Spinout of Jupiter Endovascular

Jupiter Endovascular Exits Stealth With $21M in New Financing to Fund Pivotal Trial for Pulmonary Embolism

Intuitive Announces Third Quarter Earnings

Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That's Expected to be a $7.2 Billion Market by 2029

Meta-analysis published in Annals of Surgery shows benefits of da Vinci surgery across seven oncologic procedures compared to laparoscopic and open

Management

Intuitive Announces Executive Leadership Changes to Support Continued Global Growth

Intuitive Announces Preliminary Fourth Quarter and Full Year 2024 Results

Intuitive Announces Plans to Establish Direct Presence in Italy, Spain, Portugal

Comments

Intuitive Surgical

Intuitive Surgical (ISRG) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga